Geode Capital Management’s IVERIC bio ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-2,587,857
| Closed | -$63M | – | 4800 |
|
|
2023
Q1 | $63M | Buy |
2,587,857
+172,028
| +7% | +$3.77M | 0.01% | 1018 |
|
|
2022
Q4 | $51.7M | Buy |
2,415,829
+355,148
| +17% | +$7.58M | 0.01% | 1124 |
|
|
2022
Q3 | $37M | Buy |
2,060,681
+74,646
| +4% | +$980K | 0.01% | 1304 |
|
|
2022
Q2 | $19.1M | Sell |
1,986,035
-4,572
| -0.2% | -$57.4K | ﹤0.01% | 1804 |
|
|
2022
Q1 | $33.5M | Buy |
1,990,607
+11,196
| +0.6% | +$165K | ﹤0.01% | 1540 |
|
|
2021
Q4 | $33.1M | Buy |
1,979,411
+343,337
| +21% | +$5.63M | ﹤0.01% | 1615 |
|
|
2021
Q3 | $26.6M | Buy |
1,636,074
+189,008
| +13% | +$2.06M | ﹤0.01% | 1761 |
|
|
2021
Q2 | $9.13M | Buy |
1,447,066
+112,086
| +8% | +$723K | ﹤0.01% | 2519 |
|
|
2021
Q1 | $8.25M | Buy |
1,334,980
+186,427
| +16% | +$1.13M | ﹤0.01% | 2490 |
|
|
2020
Q4 | $7.94M | Buy |
1,148,553
+84,400
| +8% | +$540K | ﹤0.01% | 2319 |
|
|
2020
Q3 | $6M | Buy |
1,064,153
+499,350
| +88% | +$2.38M | ﹤0.01% | 2284 |
|
|
2020
Q2 | $2.88M | Buy |
564,803
+284,630
| +102% | +$1.19M | ﹤0.01% | 2637 |
|
|
2020
Q1 | $963K | Buy |
280,173
+64,464
| +30% | +$377K | ﹤0.01% | 3038 |
|
|
2019
Q4 | $1.85M | Buy |
215,709
+41,935
| +24% | +$150K | ﹤0.01% | 3039 |
|
|
2019
Q3 | $194K | Hold |
173,774
| – | – | ﹤0.01% | 3778 |
|
|
2019
Q2 | $225K | Hold |
173,774
| – | – | ﹤0.01% | 3759 |
|
|
2019
Q1 | $245K | Hold |
173,774
| – | – | ﹤0.01% | 3672 |
|
|
2018
Q4 | $208K | Hold |
173,774
| – | – | ﹤0.01% | 3663 |
|
|
2018
Q3 | $410K | Hold |
173,774
| – | – | ﹤0.01% | 3538 |
|
|
2018
Q2 | $474K | Hold |
173,774
| – | – | ﹤0.01% | 3464 |
|
|
2018
Q1 | $476K | Hold |
173,774
| – | – | ﹤0.01% | 3419 |
|
|
2017
Q4 | $542K | Sell |
173,774
-12,779
| -7% | -$35.9K | ﹤0.01% | 3327 |
|
|
2017
Q3 | $526K | Hold |
186,553
| – | – | ﹤0.01% | 3339 |
|
|
2017
Q2 | $477K | Sell |
186,553
-54,018
| -22% | -$147K | ﹤0.01% | 3372 |
|
|
2017
Q1 | $880K | Buy |
240,571
+7,501
| +3% | +$31.7K | ﹤0.01% | 3078 |
|
|
2016
Q4 | $1.12M | Buy |
233,070
+8,789
| +4% | +$261K | ﹤0.01% | 2932 |
|
|
2016
Q3 | $10.3M | Sell |
224,281
-181
| -0.1% | -$10.2K | 0.01% | 1474 |
|
|
2016
Q2 | $11.5M | Buy |
224,462
+16,250
| +8% | +$807K | 0.01% | 1337 |
|
|
2016
Q1 | $8.8M | Sell |
208,212
-2,414
| -1% | -$123K | ﹤0.01% | 1479 |
|
|
2015
Q4 | $16.5M | Buy |
210,626
+10,390
| +5% | +$601K | 0.01% | 1020 |
|
|
2015
Q3 | $8.11M | Buy |
200,236
+99,517
| +99% | +$5.27M | ﹤0.01% | 1484 |
|
|
2015
Q2 | $5.24M | Buy |
100,719
+16,654
| +20% | +$828K | ﹤0.01% | 1857 |
|
|
2015
Q1 | $3.91M | Buy |
84,065
+2,066
| +3% | +$107K | ﹤0.01% | 2007 |
|
|
2014
Q4 | $3.68M | Buy |
81,999
+3,222
| +4% | +$135K | ﹤0.01% | 2014 |
|
|
2014
Q3 | $3.07M | Buy |
78,777
+1,481
| +2% | +$58.1K | ﹤0.01% | 2097 |
|
|
2014
Q2 | $3.27M | Buy |
77,296
+14,655
| +23% | +$538K | ﹤0.01% | 2076 |
|
|
2014
Q1 | $2.24M | Buy |
62,641
+7,679
| +14% | +$259K | ﹤0.01% | 2269 |
|
|
2013
Q4 | $1.78M | Buy |
+54,962
| New | +$1.63M | ﹤0.01% | 2371 |
|
Other funds holding ISEE
Geode Capital Management's ISEE Position: Q2 2023 in Review
Geode Capital Management sold out of IVERIC bio (ISEE) in Q2 2023, closing a stake of 2,587,857 shares — an estimated $63M sold.
Geode Capital Management first reported a position in ISEE in Q4 2013 and held it in 38 quarters. The position peaked at $63M in Q1 2023. 255 funds tracked by Wall St. Rank hold ISEE as of Q2 2023.
- Geode Capital Management reported no remaining IVERIC bio position as of Q2 2023 after selling out during the quarter.
- Geode Capital Management sold 2,587,857 IVERIC bio shares in Q2 2023, an estimated $63M.
- Geode Capital Management first reported a position in IVERIC bio in Q4 2013 and held it in 38 quarters.
- Geode Capital Management's IVERIC bio position peaked at $63M in Q1 2023.
- 255 funds tracked by Wall St. Rank held IVERIC bio as of Q2 2023.
Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.